(Q36307569)

English

Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma

scientific article published on January 1, 1992

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma (English)

1 reference

Europe PubMed Central

13 August 2017

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

author name string

P. A. Palmer

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627369

17 October 2022

J. Vinke

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627369

17 October 2022

P. Evers

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627369

17 October 2022

C. Pourreau

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627369

17 October 2022

R. Oskam

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627369

17 October 2022

G. Roest

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627369

17 October 2022

F. Vlems

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627369

17 October 2022

L. Becker

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627369

17 October 2022

E. Loriaux

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627369

17 October 2022

C. R. Franks

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627369

17 October 2022

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 1992

1 reference

Europe PubMed Central

13 August 2017

full work available at URL

https://api.elsevier.com/content/article/PII:095980499290450G?httpAccept=text/xml

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

https://api.elsevier.com/content/article/PII:095980499290450G?httpAccept=text/plain

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

European Journal of Cancer

1 reference

Europe PubMed Central

13 August 2017

28A

1 reference

Europe PubMed Central

13 August 2017

6-7

1 reference

Europe PubMed Central

13 August 2017

1038-1044

1 reference

Europe PubMed Central

13 August 2017

Long term culture of tumour-specific cytotoxic T cells

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/268154A0

Interleukin-2: inception, impact, and implications

1

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

Continuous proliferation of murine antigen-specific helper T lymphocytes in culture

3

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses

4

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

5

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

9

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

10

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma

13

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre study

14

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

16

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

Reporting results of cancer treatment

17

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

Nonparametric Estimation from Incomplete Observations

18

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

Evaluation of survival data and two new rank order statistics arising in its consideration

19

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.

21

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors

25

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma

27

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials

28

1 reference

10.1016/0959-8049(92)90450-G

https://api.crossref.org/works/10.1016/0959-8049(92)90450-G

17 October 2022

Identifiers

10.1016/0959-8049(92)90450-G

1 reference

Europe PubMed Central

13 August 2017

release_zozvqji45bajbhe2wpfh42w6fy

1 reference

https://api.fatcat.wiki/v0/release/zozvqji45bajbhe2wpfh42w6fy

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

13 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36307569&oldid=1843424614"